Simulations Plus stock leaves Nasdaq after Altaris takeover closes
Published on 10/31/2026 at 01:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAltaris Deal Changes Ownership
- Shareholders received cash consideration as Simulations Plus became a privately held company.
- The combination with Chemical Computing Group expands the group across drug discovery, molecular modeling and development.
Simulations Plus completed its acquisition by affiliates of Altaris on October 6, 2026, ending the company's tenure as a publicly traded business. Shareholders received $18.50 in cash per share, according to the Simulations Plus announcement.
Takeover Ends Public Listing
The transaction made Simulations Plus a privately held company, and its common stock ceased trading on the Nasdaq Global Select Market. The company said the transaction was originally announced on June 16, 2026.
Simulations Plus is being combined with Chemical Computing Group, an Altaris portfolio company focused on molecular modeling and drug discovery software. The combined organization is intended to cover a wider part of the pharmaceutical research and development process, from drug discovery and modeling to development workflows.
The ownership change removes Simulations Plus from the public equity market and changes the information available to former public-market investors. The company said it will continue operating under the Simulations Plus name and brand within the combined business.
Software Focus Meets Larger Market
Simulations Plus develops software and services for pharmaceutical research, drug development and regulatory decision-making. Its portfolio includes GastroPlus for mechanistic drug absorption and pharmacokinetic modeling, MonolixSuite for pharmacometrics, ADMET Predictor for machine-learning-based drug design and DILIsym for quantitative systems toxicology.
In the biosimulation market, Simulations Plus operates as a specialist alongside broader platforms from Certara and Dassault Systemes' BIOVIA, which are listed with the company in a Research and Markets industry report. Its product range is concentrated on model-informed drug development, pharmacokinetics, safety modeling and related pharmaceutical workflows.
Company Profile and Competition
Simulations Plus is a US-based developer of modeling, simulation and AI-enabled software for pharmaceutical and biotechnology customers. Its main markets include drug discovery, preclinical research, clinical development and regulatory support. The company has a specialized position in biosimulation, while Certara and Dassault Systemes' BIOVIA offer broader or more diversified platforms in adjacent parts of the market. Following the Altaris transaction, Simulations Plus is being paired with Chemical Computing Group to connect biosimulation with molecular modeling and drug discovery capabilities.
Simulations Plus Transaction Facts
- Transaction: Acquisition by affiliates of Altaris
- Completion date: October 6, 2026
- Shareholder consideration: $18.50 in cash per share
- Ownership: Privately held after completion
- Combination partner: Chemical Computing Group
